Melanocytic lesions are heterogeneous entities that occasionally exhibit subtle differences between benign and malignant subtypes. The incidence and mortality of melanoma are rising rapidly. Despite ongoing research and the introduction of new therapeutic methods, advanced melanoma is still considered incurable. Numerous histologic criteria are used to diagnose melanoma, but none alone are sufficient to establish this diagnosis. Therefore, differentiating between benign melanocytic lesions and melanoma may be difficult. In some cases PRAME is targeted as a potential biomarker for diagnosis of melanocytic lesions therefore there is a need to study PRAME expression by immunohistochemistry (IHC)
Aim of the work:
To detect the expression of PRAME in cutaneous melanocytic lesions and its utility to differentiate between melanoma and benign melanomcytic lesions.
Methods:
This study was carried out on fifty cases with melanocytic lesions both sexes and age from 4 to 70 years. Twenty cases were newly diagnosed cases recruitedfrom the Outpatient Clinic of Dermatology, Venereology and Andrology Department, Alexandria Main University Hospital and thirty cases retrospectively retrieved from the archives of Dermatology and pathology Departments, Faculty of Medicine, University of Alexandria